LeMaitre Lifts 2026 Outlook and Buys B. Braun Vascular Assets for $19.2M
LMAT is trading near its 52-week low of $78.22 (0.3% above the low).
Summary
LeMaitre raised its full-year 2026 sales and EPS guidance while reporting Q3 sales of $67.97 million, up 11% year over year and above estimates. Adjusted EPS of $0.65 missed, so the quarter itself was mixed — the guidance raise is the bigger item. Separately, the company bought select B. Braun vascular assets for $19.2 million; those products generated $9.4 million in 2025 sales, a modest bolt-on relative to LeMaitre's size. The distribution transition is expected to run 18-24 months, so the revenue contribution phases in rather than landing at once. This follows yesterday's Q3 release and 8-K, and comes with the stock trading near its 52-week low of $78.22, so the raised outlook and tuck-in deal give the market something to work with after a soft EPS print.
At the time of this announcement, LMAT was trading at $78.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $78.22 to $118.01. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.